We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Patient Specific Induced Pluripotency Stem Cells (PSiPS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00953693
Recruitment Status : Completed
First Posted : August 6, 2009
Last Update Posted : December 27, 2012
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
Induced pluripotent stem cells (iPSCs) are adult cells that have been genetically reprogrammed to an embryonic stem cell-like state by being forced to express genes and factors important for maintaining the defining properties of embryonic stem cells. The reprogramming of adult cells into embryonic stem (ES) cells enables the generation of patient-specific stem cells and thus has enormous potential for the treatment and analysis of degenerative diseases. In this project the investigators are going to induce pluripotent stem cells from cell cultures from skin biopsies of patients. The iPS cells will be developed for modeling diseases and drug discovery as well as basic research.

Condition or disease Intervention/treatment
Hepatic Disorders Eye Disorders Procedure: Biopsy

Detailed Description:
iPS cells are typically derived by transfection of certain stem cell-associated genes into non-pluripotent cells, such as adult fibroblasts. Transfection is typically achieved through viral vectors, such as retroviruses. Transfected genes include the master transcriptional regulators Oct-3/4 (Pouf51) and Sox2, although to enhance the efficiency of induction some other genes e.g. Klf4, c-Myc. In this study after separation the fibroblasts from patient`s skin biopsy, the cells are transfected with 4 Yamanaka factors (human Oct4, Sox2, Klf4, c-Myc) after 3-4 weeks, transfected cells are isolated through morphological selection.

Study Design

Study Type : Observational
Estimated Enrollment : 15 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Patient Specific Induced Pluripotency Stem Cells (PSiPS)
Study Start Date : April 2009
Primary Completion Date : January 2010
Study Completion Date : July 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Biopsy
U.S. FDA Resources

Groups and Cohorts

Intervention Details:
    Procedure: Biopsy
    Skin biopsy

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years to 80 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
The patient who suffering from metabolic disorders
Criteria

Inclusion Criteria:

  • Donors suffering from different (specified) metabolic disorders
  • Donors suffering from different (specified) eye disorders which resulted to blindness
  • Special blood group: O Bombay

Exclusion Criteria:

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00953693


Locations
Iran, Islamic Republic of
Royan Institute
Tehran, Iran, Islamic Republic of
Sponsors and Collaborators
Royan Institute
Investigators
Study Chair: Hamid Gourabi, PhD Royan Institute
Study Director: Hossein Baharvand, PhD Royan Institute
More Information

Additional Information:
Publications:
Responsible Party: Royan Institute
ClinicalTrials.gov Identifier: NCT00953693     History of Changes
Other Study ID Numbers: Royan-iPS-001
First Posted: August 6, 2009    Key Record Dates
Last Update Posted: December 27, 2012
Last Verified: April 2010

Keywords provided by Royan Institute:
Induced pluripotent stem cells
Hepatic disorders
Eye disorders
Blood groups

Additional relevant MeSH terms:
Disease
Liver Diseases
Eye Diseases
Pathologic Processes
Digestive System Diseases